Prevalence of Breastfeeding in Infants With Down Syndrome: A Systematic Review and Meta-Analysis.

Acta PaediatrJul 3, 2026 (epub)
Clinical ResearchMedical GeneticsPediatrics

Mélina Balland, Julia Prillard, Irène Loras-Duclaux et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prevalence of breastfeeding in infants with Down syndrome, analyzing data from 26 studies involving 3463 infants. The overall prevalence of breastfeeding was found to be 71.6%, while exclusive breastfeeding prevalence was 38.4%. High heterogeneity was noted in the results.

Key findings

  • Overall breastfeeding prevalence in infants with Down syndrome was 71.6% (95% CI [60.3; 80.7]).
  • Exclusive breastfeeding prevalence was 38.4% (95% CI [22.4; 57.3]).
  • No factors assessed were significantly associated with overall breastfeeding rates.

Why it matters

Understanding breastfeeding prevalence in infants with Down syndrome is crucial for developing targeted support strategies. This knowledge can help healthcare providers address specific challenges faced by these families.

Source

PubMed · PMID 42397686

Published in Acta Paediatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Medical Genetics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.